With $4.9B FortySevenInc acquisition GileadSciences expands Cancer immunotherapy pipeline with magrolimab and two clinicbound candidates httpow.ly3Vmj50yAy5ZÂpic.twitter.coml6UvxAj8ML
With $4.9B @FortySevenInc acquisition, @GileadSciences expands #Cancer #immunotherapy pipeline with magrolimab and two clinic-bound candidates: http://ow.ly/3Vmj50yAy5Z pic.twitter.com/l6UvxAj8ML
More From BioPortfolio on "With $4.9B @FortySevenInc acquisition, @GileadSciences expands #Cancer #immunotherapy pipeline with magrolimab and two clinic-bound candidates: http://ow.ly/3Vmj50yAy5Z pic.twitter.com/l6UvxAj8ML"